FILANA THERAPEUTICS, INC.
FLNANext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for FLNA. That does not mean none is planned.
Get an email about FLNA's next catalysts
Track FILANA THERAPEUTICS (FLNA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 1 past
FLNA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
How FLNA's past catalysts played out
Market Overview
Stock performance and key metrics
Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam (previously known as PTI-125 and sumifilam), an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
Website| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Simufilam | Phase 3 | Alzheimer Disease | - | - |
Frequently asked questions
What is in FILANA THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in FILANA THERAPEUTICS, INC.'s (FLNA) pipeline across Phase 3. Its lead program is Simufilam (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is FILANA THERAPEUTICS, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for FILANA THERAPEUTICS, INC. (FLNA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track FLNA biotech catalysts?→
Add FLNA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow FILANA THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.